Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC — Investor Relations & Filings

Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 416 across all filing types
Latest filing 2020-10-12 Major Shareholding Noti…
Country GB United Kingdom
Listing IL AGY

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly labeled as 'TR-1: Standard form for notification of major holdings' and carries an 'RNS Number'. It details changes in voting rights percentages (crossing the 20.1% threshold) for a specific shareholder (Sky Gem Acquisition Limited) in Allergy Therapeutics Plc, dated October 12, 2020. This type of filing, which reports changes in significant share ownership, directly corresponds to the Major Shareholding Notification category (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2020-10-12 English
Director Dealings and Issue of Equity
Director's Dealing Classification · 99% confidence The document is an official announcement released via RNS (RNS Number : 5729B) on October 9, 2020. The content explicitly details transactions involving a director (Manuel Llobet, CEO), specifically the exercise of options and subsequent sale of ordinary shares. This directly matches the definition of Director's Dealing (insider trades). The structure, including the notification table conforming to EU Market Abuse Regulation requirements, confirms this classification. Therefore, the appropriate code is DIRS.
2020-10-09 English
Preliminary Results
Earnings Release Classification · 100% confidence The document explicitly states it contains 'Preliminary Results for the year ended 30 June 2020' and provides detailed financial highlights (revenue growth, operating profit, net profit, cash balance) and operating highlights for the full fiscal year. This structure, covering a full 12-month period with preliminary figures, strongly indicates an Annual Report or a document closely associated with it, such as an Earnings Release (ER) or Interim Report (IR). However, since it covers the full year and contains extensive management and chairman reports alongside financial data, it is most accurately classified as the preliminary announcement preceding the final 10-K, or a comprehensive annual summary. Given the options, 'ER' (Earnings Release) is the closest fit for a preliminary announcement of annual results, although '10-K' is the final official filing. Since this is a preliminary announcement of *annual* results, and it is not a short announcement linking to a full report (ruling out RPA/RNS based on length and content), it functions as the primary annual results disclosure. In many contexts, the preliminary results announcement is categorized as an Earnings Release (ER) when it precedes the formal 10-K filing. The presence of the RNS Number (7973Z) confirms it is a regulatory disclosure, but the content is clearly the annual financial summary. FY 2020
2020-09-23 English
AGY secures VLP technology platform
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' header and contains information typical of a regulatory news service announcement from the London Stock Exchange (LSE). The content details a significant corporate action: Allergy Therapeutics plc securing a VLP technology platform via licensing agreements with Saiba AG and DeepVax GmbH to broaden its vaccine pipeline. This is a material business development announcement. Since it is a formal announcement distributed via RNS and does not appear to be a full financial report (like 10-K or IR) or a specific proxy/remuneration document, it fits best under the general regulatory announcement category, RNS, or potentially a Capital/Financing Update (CAP) due to the licensing and future development plans. However, the primary identifier is the RNS distribution format and the nature of the news release itself, which is a general corporate update. Given the options, RNS is the most appropriate fallback for a general, material news release distributed through the official channel, although it is not a 'Report Publication Announcement' (RPA) as it is the news itself, not an announcement *about* a report. It is a standard regulatory news item.
2020-09-03 English
Second Price Monitoring Extn
Regulatory Filings Classification · 98% confidence The document is very short (1382 characters) and begins with 'RNS Number : 0922T', indicating it is a regulatory news service announcement from the London Stock Exchange. The content discusses a 'Second Price Monitoring Extension' for a security, which is a specific operational notice related to trading halts or volatility controls. This type of miscellaneous, non-standard regulatory announcement that doesn't fit the specific financial report categories (like 10-K, ER, IR) is best classified under the general regulatory filing/announcement category.
2020-07-15 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is very short (1365 characters) and is explicitly labeled as an 'RNS Number'. It announces a 'Price Monitoring Extension' related to trading activity on the London Stock Exchange. This is a general regulatory announcement that does not fit the specific definitions for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Therefore, it falls best under the general regulatory announcement category.
2020-07-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.